KalVista Pharmaceuticals (KALV) Common Equity (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Common Equity data on file, last reported at $40.8 million in Q3 2025.

• For the quarter ending Q3 2025, Common Equity fell 76.39% year-over-year to $40.8 million; the trailing twelve-month figure through Jul 2025 stood at $40.8 million (down 76.39% YoY), and the FY2025 full-year result was $95.4 million, down 53.82% from the prior year.
• Common Equity fell to $40.8 million in Q3 2025, from $95.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $257.2 million in Q2 2021 to a low of $40.8 million in Q3 2025.
• A 5-year average of $157.4 million and a median of $164.4 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 255.05% in 2022 and plunged 76.39% in 2025, its largest moves.
• Tracing KALV's Common Equity over 5 years: stood at $227.5 million in 2021, then sank by 36.78% to $143.8 million in 2022, then declined by 20.42% to $114.4 million in 2023, then soared by 43.61% to $164.4 million in 2024, then plunged by 75.18% to $40.8 million in 2025.
• Business Quant data shows KALV's Common Equity at $40.8 million in Q3 2025, $95.4 million in Q2 2025, and $164.4 million in Q4 2024.